Thyroid Profiles in Patients With Acute Illness

Thyroid Dysfunction Clinical Trial

Official title:

Thyroid Profiles in Middle Eastern Patients Admitted With Acute Illness: Prevalence, Clinical Features and Impact on Mortality

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05980923
• Other study ID #: DCR2023/1.ThyrAcuteIll
• Status: Recruiting
• Start date: October 15, 2023
• Est. completion date: October 30, 2024

Study information

• Verified date: December 2023
• Source: Jordan Collaborating Cardiology Group
• Contact: Ayman J Hammoudeh, MD, FACC
• Phone: 0096265001000
• Email: a.hammoudeh[@]istisharihospital.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Patients admitted to the hospital with acute illness may have a wide spectrum of thyroid function abnormalities. It is largely unknown whether such aberrations are temporary or persist for a long time, and whether they impact prognosis of such patients.

Description:

Recently, there has been a growing body of evidence that subclinical thyroid dysfunction as a contributor to the increase of cardiovascular events. Elevated serum thyroid-stimulating hormone (TSH) levels and normal free thyroxine (FT4) and free triiodothyronine (FT3) levels have been associated with worse heart failure and dyslipidemia. Furthermore, higher risk of atrial fibrillation has been linked tp thyroid abnormalities in these patients.

Patients admitted to the hospital with acute illness may have a wide spectrum of thyroid function abnormalities. It is largely unknown whether such aberrations are temporary or persist for a long time, and whether they impact prognosis of such patients. This study aimed at evaluating the prevalence of thyroid function abnormalities in patients admitted to hospital with acute illness and their temporal changes and impact on mortality during hospitalization and at 1 year. Serum level of thyroid stimulating hormone and free T4 and T3 measured on admission. Clinical and laboratory profiles of patients with abnormal thyroid function (ATF group) will be compared to those with normal thyroid function (NTF group). Short and long term survival of both groups were compares as well.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: October 30, 2024
• Est. primary completion date: October 15, 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Hospital admission

• Adults aged 18 years and above

• Willing to sign an informed consent

• Diagnosis on admission is acute illness that includes: heart failure, acute coronary syndrome, sepsis, acute stroke, hypotension, acute system-organ failure including renal and hepatic failure.

Exclusion Criteria:

• Age less than 18 years.

• Refusal to sign consent.

• Admission for a reason not classified as acute illness.

Related Conditions & MeSH terms

• Acute Illness
• Thyroid Diseases
• Thyroid Dysfunction

Intervention

Other:
• Performing blood thyroid test (TSH, FT4, FT3)
Blood test as above

Locations

Country	Name	City	State
Jordan	Istishari Hospital	Amman

Sponsors (1)

Lead Sponsor	Collaborator
Jordan Collaborating Cardiology Group

Country where clinical trial is conducted

Jordan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	In hospital mortality	All-cause death rate in patients with abnormal thyroid function compared with death in those with no abnormal thyroid function during the patients hospital stay..	From time of study entry until the date of death from any cause, assessed up to 2 weeks.
Secondary	6-month mortality rate	All-cause death rate in patients with abnormal thyroid function compared with death in those with no abnormal thyroid function at 6 months.	From date of study entry until the date of death from any cause, assessed up to two weeks.